Zacks Investment Research upgraded shares of Tcr2 Therapeutics (NASDAQ:TCRR) from a hold rating to a buy rating in a research report report published on Thursday, Zacks.com reports. They currently have $17.00 price target on the stock.
According to Zacks, “TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing T cell therapies for patients suffering from cancer. Its product candidate includes TC-210, TC-220, TC-410, TC-110 and TC-310 which are in clinical stage. TCR2 Therapeutics Inc. is based in Cambridge, Massachusetts. “
A number of other research firms also recently issued reports on TCRR. Roth Capital started coverage on shares of Tcr2 Therapeutics in a research report on Friday, May 31st. They set a neutral rating and a $16.00 target price for the company. ValuEngine upgraded shares of Tcr2 Therapeutics from a hold rating to a buy rating in a research report on Thursday, August 8th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Tcr2 Therapeutics has an average rating of Buy and a consensus target price of $26.00.
Tcr2 Therapeutics (NASDAQ:TCRR) last posted its earnings results on Thursday, August 8th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.11. As a group, analysts expect that Tcr2 Therapeutics will post -5.66 EPS for the current year.
A number of hedge funds and other institutional investors have recently bought and sold shares of TCRR. EcoR1 Capital LLC acquired a new position in shares of Tcr2 Therapeutics in the second quarter worth about $231,000. Charles Schwab Investment Management Inc. acquired a new position in shares of Tcr2 Therapeutics in the second quarter worth about $349,000. Laurion Capital Management LP acquired a new position in shares of Tcr2 Therapeutics in the first quarter worth about $417,000. Parametric Portfolio Associates LLC raised its position in shares of Tcr2 Therapeutics by 23.5% in the second quarter. Parametric Portfolio Associates LLC now owns 35,044 shares of the company’s stock worth $501,000 after acquiring an additional 6,672 shares during the period. Finally, Dean Capital Investments Management LLC acquired a new position in shares of Tcr2 Therapeutics in the first quarter worth about $694,000. Institutional investors own 33.26% of the company’s stock.
About Tcr2 Therapeutics
TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.
Featured Story: Quick Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.